Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.55 |
| ▸ | YAP1 | P46937 | 1/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498818 | 0.90 | YAP1 (0.54) | YAP1KLK5BCL2MAOBMEN1 | |
| SCHEMBL31539528 | 0.89 | KLK5 (0.58) | CACNA1BKLK5MEN1ALDH1A1LMNA | |
| SCHEMBL4729306 | 0.89 | KLK5 (0.58) | CACNA1BKLK5MEN1ALDH1A1LMNA | |
| SCHEMBL30547272 | 0.89 | KLK5 (0.58) | CACNA1BKLK5MEN1ALDH1A1LMNA | |
| SCHEMBL3498682 | 0.89 | CTSS (0.56) | YAP1KLK5BCL2MAOBMEN1 | |
| SCHEMBL3498679 | 0.89 | CTSS (0.56) | YAP1KLK5BCL2MAOBMEN1 | |
| SCHEMBL3350988 | 0.88 | BCL2 (0.64) | YAP1KLK5BCL2MEN1ALDH1A1 | |
| SCHEMBL3500186 | 0.88 | BCL2 (0.64) | YAP1KLK5BCL2MEN1ALDH1A1 | |
| SCHEMBL6161729 | 0.88 | BCL2 (0.64) | YAP1KLK5BCL2MEN1ALDH1A1 | |
| SCHEMBL2353801 | 0.86 | KLK5 (0.59) | CACNA1BYAP1KLK5BCL2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | CACNA1B 1462/4885YAP1 1692/4885KLK5 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.